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Purpose: Age-related macular degeneration (AMD) is a frequent, complex disorder in elderly of European
ancestry. Risk proﬁles and treatment options have changed considerably over the years, which may have affected
disease prevalence and outcome. We determined the prevalence of early and late AMD in Europe from 1990 to
2013 using the European Eye Epidemiology (E3) consortium, and made projections for the future.
Design: Meta-analysis of prevalence data.
Participants: A total of 42 080 individuals 40 years of age and older participating in 14 population-based
cohorts from 10 countries in Europe.
Methods: AMD was diagnosed based on fundus photographs using the Rotterdam Classiﬁcation. Preva-
lence of early and late AMD was calculated using random-effects meta-analysis stratiﬁed for age, birth cohort,
gender, geographic region, and time period of the study. Best-corrected visual acuity (BCVA) was compared
between late AMD subtypes; geographic atrophy (GA) and choroidal neovascularization (CNV).
Main Outcome Measures: Prevalence of early and late AMD, BCVA, and number of AMD cases.
Results: Prevalence of early AMD increased from 3.5% (95% conﬁdence interval [CI] 2.1%e5.0%) in those
aged 55e59 years to 17.6% (95% CI 13.6%e21.5%) in those aged 85 years; for late AMD these ﬁgures were
0.1% (95% CI 0.04%e0.3%) and 9.8% (95% CI 6.3%e13.3%), respectively. We observed a decreasing prev-
alence of late AMD after 2006, which became most prominent after age 70. Prevalences were similar for gender
across all age groups except for late AMD in the oldest age category, and a trend was found showing a higher
prevalence of CNV in Northern Europe. After 2006, fewer eyes and fewer 80-year-old subjects with CNV were
visually impaired (P ¼ 0.016). Projections of AMD showed an almost doubling of affected persons despite a
decreasing prevalence. By 2040, the number of individuals in Europe with early AMD will range between 14.9 and
21.5 million, and for late AMD between 3.9 and 4.8 million.
Conclusion: We observed a decreasing prevalence of AMD and an improvement in visual acuity in CNV
occuring over the past 2 decades in Europe. Healthier lifestyles and implementation of antievascular endothelial
growth factor treatment are the most likely explanations. Nevertheless, the numbers of affected subjects will
increase considerably in the next 2 decades. AMD continues to remain a signiﬁcant public health problem among
Europeans. Ophthalmology 2017;-:1e11 ª 2017 by the American Academy of Ophthalmology. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplementary material available at www.aaojournal.org.Age-related macular degeneration (AMD) can cause irre-
versible blindness and is the leading cause of visual
impairment in the elderly of European ancestry.1 Two stages
are known for this disease: early AMD, which isª 2017 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier
Inc.characterized by drusen and pigmentary changes, and late
AMD, which can be distinguished in 2 subtypesd
geographic atrophy (GA) and choroidal neovascularization
(CNV).21http://dx.doi.org/10.1016/j.ophtha.2017.05.035
ISSN 0161-6420/17
Ophthalmology Volume -, Number -, Month 2017Worldwide estimates approximated that 30e50 million
people are affected by AMD,3,4 and these numbers are ex-
pected to increase over time because of the aging pop-
ulation.1,5e9 Although multiple small studies have assessed
the prevalence of AMD and its relation to visual decline at
various places in Europe,10e12 a clear overview for Europe
as a whole is lacking.13 Comprehensive epidemiologic
ﬁgures on AMD in Europe would help proper planning
for public health and eye care policy makers.
Recent studies report a decrease in AMD-associated
blindness and visual impairment,14,15 which are likely to
be attributable to improved diagnostic procedures and hence
earlier diagnosis, and the introduction of antievascular
endothelial growth factor (VEGF) therapy.14e16 Anti-VEGF
therapy for CNV was introduced in 2004 and, since 2006, it
has been widely used for clinical care in Europe.17,18
However, the impact of anti-VEGF therapy on general vi-
sual function of persons with AMD in Europe has not been
sufﬁciently studied.1,16
In this study, we investigated the prevalence of both early
and late AMD in Europe using summary data of population-
based cohort studies from the European Eye Epidemiology
(E3) consortium. We analyzed changes in prevalence over
time, compared geographic regions, and studied differences
between men and women. Moreover, we analyzed the visual
acuity of affected individuals before and after the intro-
duction of anti-VEGF therapy and predicted the number of
persons with AMD by 2040 in Europe.
Methods
Study Population
Fourteen population-based cohort studies participating in the E3
consortium contributed to this analysis. This consortium consists of
European studies with epidemiologic data on common eye disor-
ders; a detailed description on the included studies has been pub-
lished elsewhere.16 For the current analysis, studies with gradable
macular fundus photographs (n ¼ 42 080 participants) and
participants aged 40 years and over provided summary data.
Participants were recruited between 1990 and 2013 from the
following countries: Estonia, France, Germany, Greece, Italy,
Northern Ireland, Norway, Netherlands, Spain, Portugal,19,20 and
the United Kingdom (UK)16 (Table 1). The composition of AMD
in each cohort is shown in Figure 1 (available at
www.aaojournal.org). The study was performed in accordance
with the Declaration of Helsinki for research involving human
subjects and the good epidemiologic practice guideline.
Grading of Age-Related Macular Degeneration
Both eyes of each participant were graded and classiﬁed separately
by experienced graders or clinicians, and the most severe AMD
grade of the worse eye was used for classiﬁcation of the person. To
harmonize classiﬁcation of AMD, studies were graded or reclas-
siﬁed according to the Rotterdam Classiﬁcation, as previously
described.21 Main outcomes of this study were early AMD (grade 2
or 3 of the Rotterdam Classiﬁcation) and late AMD (grade 4 of the
Rotterdam Classiﬁcation). Persons with late AMD were stratiﬁed
as GA and CNV or mixed (both GA and CNV present in one
person, either both types in the same eye or one type per eye),2which is henceforth in this article referred to as CNV. The
Tromsø Eye Study, the Thessaloniki Eye Study, and the
European Prospective Investigation into Cancer and Nutrition
(EPIC) study had fundus photograph grading that could not be
converted to match the deﬁnition of early AMD of the
Rotterdam Classiﬁcation. Therefore, these 3 studies only
participated in the late AMD analysis.
Visual Impairment
Visual acuity was measured for each eye separately as best-
corrected visual acuity in 2 categories: 0.3 and <0.3. When
best-corrected visual acuity differed in the 2 eyes, visual acuity of
the best eye was used to classify the person. Low vision and
blindness were deﬁned as visual acuity <0.3 and further referred to
as visually impaired.
Projection of Age-RelatedMacular Degeneration
The projection of AMD cases in Europe from 2013 to 2040 was
calculated using the prevalence data for 5-year age categories ob-
tained from the meta-analysis. Two different scenarios were used
to calculate the projection. In the ﬁrst scenario, it was assumed that
the prevalence of both early and late AMD will remain stable until
2040. This scenario accounted for changes in population structure
only. The second scenario followed the trend of decreasing prev-
alence based on data from the meta-analysis of the E3 consortium
regarding the period 2006e2013. We calculated the rate of decline,
with 2013 as the starting point and 2040 as the end point, and made
the assumption that the rate of decline was decelerating and zero at
the end point. For each projected year, prevalences were calculated
for every 5-year age group, for early AMD from 45 years of age
and onward and for late AMD 65 years and onward. The projected
prevalences were then multiplied by the predicted European pop-
ulation estimates obtained from Eurostat for all 28 countries in
Europe, and the sum of individuals from all age groups was
calculated.22
Statistical Analysis
The crude prevalence of early and late AMD were calculated per
study for each 5-year age group. A random-effects meta-analysis
was performed by weighing the studies according to sample size,
for early and late AMD separately for 5-year age groups and for
people aged 70 years and older. In case of reported zero preva-
lence, the Haldane correction was used.23 In the case of 100%
prevalence, 0.01 was subtracted to prevent exclusion from the
analysis. This analysis was repeated, stratiﬁed for the midpoint
year of the study recruitment period, before and after the year
2006 and for 10-year birth cohorts. Furthermore, it was repeated
for gender, and for geographical area in Europe based on the
United Nations Geoscheme.24 A chi-square test was used to
compare time trends.
In addition, a meta-analysis was performed for eyes with visual
impairment owing to late AMD, and per subtype of late AMD.
Subsequently, the analysis was stratiﬁed for studies conducted
before and after 2006, for which the midpoint year of the study
recruitment period was used. The number of visually impaired
people was calculated before and after 2006. Meta-analysis was
performed with Stata software (release 13, version 13.1; StataCorp
LP, College Station, TX) using metaprop. Graphical outputs were
constructed with GraphPad Prism 7 (for Windows; GraphPad
Software, La Jolla, CA; www.graphpad.com).
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Colijn et al  Prevalence of AMD in Europe: Past and FutureResults
The total study population included in this analysis consisted of
42 080 individuals from 14 studies with a median age of 65e69
years and a slight female predominance (55.8%). The prevalence
of all age groups together varied per study between 2.3% and
16.8% for early AMD (total N ¼ 2703) and between 0.2% and
5.6% for late AMD (total N ¼ 664) (Fig 2A and B, available at
www.aaojournal.org; to avoid biased estimates only groups larger
than 30 individuals are shown; this applied only to the Rotterdam
Study 3 age category 85 years). Owing to moderate to high
heterogeneity (I2 75% in 73 of 141 analyses), which was not
related to time trends, we applied a random-effects model for
each meta-analysis. This provided a prevalence of early AMD
increasing with age from 3.5% (95% conﬁdence interval [CI]
2.1%e5.0%) at 55e59 years to 17.6% (95% CI 13.6%e21.5%)
in persons aged 85 (Fig 3A, and Table 2, available at
www.aaojournal.org). The prevalence of late AMD rose from
virtually zero in the youngest age group to 9.8% (95% CI
6.3%e13.3%) for those in the highest age group (Fig 3B).
Taking together all people aged 70 years, the overall
prevalence was 13.2% (95% CI 11.2%e15.1%) for early AMD
and 3.0% (95% CI 2.2%e3.9%) for late AMD. We
investigated prevalence changes over time by dividing the E3
consortium into studies conducted before and after 2006. The
prevalence of early AMD before and after 2006 seemed to rise
with age in a similar fashion. For late AMD, a trend of
decreasing prevalence was observed for the higher age
categories after 2006 (Fig 3C and D). Even after exclusion of
the 2 cohorts (Rotterdam Study [RS]-II and European Eye
Study [EUREYE]) with the highest prevalences in the highest
age category before 2006, results remained similar (data not
shown). When we analyzed prevalence data as a function of
birth cohort, a relatively stable prevalence of early AMD was
visible across all birth cohorts, whereas a decreasing prevalence
of late AMD was seen for the more recent birth cohorts (Fig
4A and B).
Gender and Geographic Region
We studied the relation with gender and found no differences in the
prevalence of early and late AMD between men and women except
for the age category of 85 years and older for late AMD (Fig 5A
and B, available at www.aaojournal.org). This category shows a
trend for a higher prevalence in women compared to men,
although CIs overlap.
Toaddress differential distribution ofAMDinEurope,we stratiﬁed
studies according to 3 regions deﬁnedby theUnitedNations.24 In older
individuals, we observed a trend toward a higher prevalence of early
AMD in the North (16% in those 70 years; 95% CI 14%e17%)
compared to the West (12%; 95% CI 10%e14%) and South (14%;
95% CI 10%e17%) (Fig 6A, available at www.aaojournal.org).
Likewise, late AMD had the highest prevalence in the North (4.2%;
95% CI 2%e6%) compared to the West (3.1%; 95% CI 2%e4%)
and South (3.1%; 95% CI 2%e4%) (Fig 6B, available at
www.aaojournal.org). More detailed analyses showed that a
frequency difference was only present for CNV (Fig 6C and D,
available at www.aaojournal.org); however, CIs of the regional
differences overlapped.
Visual Consequences
As most countries implemented anti-VEGF therapy for CNV
from 2006 onward, we compared visual impairment from AMD
in studies carried out before and after this year. Before 2006,3
Figure 3. Meta-analysis of (A) early and (B) late age-related macular degeneration (AMD) in Europe per age category for the participating studies. Meta-
analysis of the prevalence of (C) early and (D) late AMD before and after 2006.
Ophthalmology Volume -, Number -, Month 201754.2% of eyes with GA were visually impaired, and 79.8% of
eyes suffering from CNV were visually impaired. From 2006
onward, the proportion of visually impaired eyes remained the
same for GA (47.6%; P ¼ 0.40), but dropped to 66.2% (P ¼
0.026) for CNV (Fig 7A). This improvement was also observed
for the number of bilaterally visually impaired persons; 120 of
345 (34.8%) before 2006 to 75 of 259 (28.9%; P ¼ 0.13) after
2006. The largest drop was seen for people aged 80 years and
older; 85 of 175 (48.6%) before 2006 to 46 of 132 (34.8%;
P ¼ 0.016) after 2006 (Fig 7B).Figure 4. Meta-analysis of early (A) and late (B) age-related macular degenera
4Projections of Age-Related Macular
Degeneration in Europe for 2040
Assuming that the prevalence of early and late AMD will remain
stable over time, an increase from 15.0 million in 2013 to 21.5
million for early AMD can be expected by 2040. The number of
people with late AMD will almost double during this time period,
from 2.7 million in 2013 to 4.8 million in 2040.
Assuming a more realistic scenario for which E3 historic data
and a decelerating slope were used, we found that the prevalence oftion in Europe by 10-year birth cohorts.
Figure 7. A, Proportion of visually impaired eyes within each subgroup of late age-related macular degeneration (AMD). The proportion of visually
impaired eyes remained the same for geographic atrophy (47.6%; P ¼ 0.4), but dropped to 66.2% (P ¼ 0.026) for choroidal neovascularization after 2006. B,
Proportion of persons with late AMD with bilateral visual impairment before and after 2006 (P ¼ 0.016). * Corresponds with P < 0.05.
Colijn et al  Prevalence of AMD in Europe: Past and Futureearly AMD will ﬁrst decrease and then slightly increase between
2013 and 2040. The model estimated that the number of people
with early AMD would remain almost the same: from 15.0 million
in 2013 to 14.9 million in 2040. This model also displayed that the
number of people with late AMD in Europe will increase from 2.7
million in 2013 to 3.9 million by 2040 (Fig 8).Discussion
Age-Related Macular Degeneration Prevalence
and Its Time Trends
Our study provides insight into the prevalence of both
early and late AMD in Europe. Based on meta-analyzed
data from 14 population-based cohort studies included in
the E3 consortium, the overall prevalence of early and late
AMD was 13.2% and 3.0%, respectively, in the age
category 70 years. These estimates are comparable to
those among persons of European descent living in other
continents.4,25
Our data show a trend toward a slightly decreasing
prevalence of AMD in the older age categories. It is unlikely
that this is explained by differential mortality in AMD pa-
tients before and after 2006, although studies have shown
conﬂicting results on death as a competing risk factor for
AMD, and we cannot exclude that this plays a role.26e28
The decreasing trend in time has also been observed in
the Beaver Dam Eye Study, indicating that these trends are
not conﬁned to Europe.29 Decreasing rates have also been
observed for other aging disorders such as cardiovascular
disease and dementia,30e33 and may be related to
improved lifestyle among the elderly34e36; for example, the
number of smokers declined by 30.5% from 1990 to 2010 in
Europe.37 Taken together, the decline in prevalence suggests
that the increases in the number of AMD patients may not
be as substantial as previous prediction studies suggested.38
Gender and Geographic Regions
Our data showed no difference in the prevalence of early
and late AMD with respect to gender. In the oldest age
category of 85 years and older, women seemed to have ahigher prevalence of late AMD, but detailed analysis
showed that this was mostly owing to imprecision of the
estimate in men, caused by a lower number of men in this
age group (Fig 9, available at www.aaojournal.org). This
has also been observed in other studies.7,39
As for regional differences, we noticed that the northern
region of Europe showed a slightly higher prevalence of early
and late AMD. This trend was the result of a higher prevalence
of CNV in the north. Our ﬁndings are in concordance with the
results previously published by the Tromsø Eye Study40 but
are in contrast with other studies performed in the north of
Europe ﬁnding a higher prevalence of GA (EUREYE,
Reykjavik Eye Study, and Oslo Macular Study).41e43
Considering the larger sample size and high response rate of
the Tromsø Eye Study compared with the other studies, these
ﬁndings might be more legitimate. No consistent differences
were observed for the western and southern regions of Europe.
Visual Consequences
The proportion of eyes affected by CNV that were visually
impaired was reduced after the year 2006. Unfortunately,
our study lacked actual data on interventions for CNV, but it
is likely that the reduction is attributable to the use of anti-
VEGF injections, which were introduced as a therapy for
CNV in Europe from 2006 onward.18 This notion is
supported by ﬁndings from clinical trials44,45 and other
studies, which show an up to 2-fold decrease in legal
blindness due to AMD after 2006.14,15,46,47 The public
campaigns that were initiated after the introduction of anti-
VEGF have undoubtedly contributed to the reduction of
visual loss, as they made elderly persons more aware of the
symptoms and stimulated prompt therapy.48,49
Projections of Age-Related Macular
Degeneration in Europe
It is unclear whether the prevalence of AMD will decrease
even more in the coming years, but an increase is not likely
to be expected. Therefore, we projected the estimated
number of AMD-affected persons until the year 2040 based
on 2 different scenarios: 1 based on stable prevalence and 15
Figure 8. Predicted number of persons with age-related macular degenera-
tion (AMD) in years 2013e2040 as a function of 2 prevalence scenarios.
Ophthalmology Volume -, Number -, Month 2017following the trend of declining prevalences. The results of
the ﬁrst scenario suggests that the absolute number of per-
sons with late AMD will increase by 2.1 million, a 1.5-times
increase. A Norwegian study predicted, under the assump-
tion of a stable prevalence, the same relative increase of
affected subjects, with a total of 328 000 cases of late AMD
in Scandinavia by 2040.5,8 A study in the United States
calculated a 2.2-times increase in absolute numbers and
estimated a total number of affected subjects to be 3.8
million by 2050.5,8 Worldwide projections have shown a
doubling of late AMD and an increase of 9 million cases by
2040.4
The second scenario was based on declining rates, and
showed a small increase in the number of people with early
AMD, from 14 million in 2016 to 14.9 million by 2040, and
a larger relative increase in the number of people with late
AMD, from 2.7 million in 2016 to 3.9 million by 2040.
Considering the declining rates of smoking and imple-
mentation of healthier diets in elderly persons, the second
projection may be more legitimate.First Name Last Name In
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Appendix
The E3 Consortium
6Study Limitations
A limitation to this E3 consortium meta-analysis is the het-
erogeneity across studies regarding study design and inclusion
criteria. For example, age at inclusion and method of recruit-
ment varied between studies. Although in every study AMD
was classiﬁed according to the Rotterdam Classiﬁcation,
studies differed in AMD grading, especially for pigmentary
changes and drusen size. Given the heterogeneity, we therefore
performed a random-effects meta-analysis for both early and
late AMD. Furthermore, patient management and access to
health care may have differed between study sites, resulting in
differences in preventive and treatment options.50,51
When data collection started in 1990, fundus photography
was the gold standard for grading AMD. Since 1990, imaging
techniques evolved rapidly, greatly improving the diagnosis
ofAMD featureswith non-invasive techniques such as optical
coherence tomography, autoﬂuorescence, and near-infrared
photographs. In addition, multimodal imaging better visual-
izes edema and subtle changes resulting from CNV, which
may not be so apparent when the patient was treatedwith anti-
VEGF therapy.52,53 Although macular edema due to sub-
retinal neovascularization often coincides with prominent
retinal changes such as hemorrhages or hard exudates, our
data may have underestimated the true prevalence of CNV.53
In summary, this study estimates the prevalence of early
and late AMD per age category in Europe over the past two
decades. Prevalence of both these forms remained stable or
decreased slightly. Nevertheless, we observed a signiﬁcant
reduction in the proportion of visually impaired eyes
attributable to CNV after 2006. Unfortunately, due to the
aging population, the number of people with AMD will
increase during the next decades, indicating a continuous
need to develop comprehensive modalities for prevention
and treatment of AMD.stitution City Country
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